natgillin/translations-raw huggingface dataset:
NAME OF THE VETERINARY MEDICINAL PRODUCT CORTAVANCE 0.584 mg/ml cutaneous spray solution for dogs 
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA CORTAVANCE 0,584 mg/ml sprej za kožu otopina za pse
MARKETING AUTHORISATION NUMBER(S) Carton with a PET bottle of 31ml: EU/2/06/069/002 
16. BROJ(EVI) ODOBRENJA ZA STAVLJANJE U PROMET Kutija s PET bočicom od 31ml: EU/2/06/069/002
MARKETING AUTHORISATION NUMBER(S) PET bottle of 76ml: EU/2/06/069/001 
16. BROJ(EVI) ODOBRENJA ZA STAVLJANJE U PROMET PET bočica od 76 ml: EU/2/06/069/001
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE Bottle of 76 ml 
PODACI NA UNUTARNJEM PAKOVANJU Polietilenska (PET) boca od 76 ml
EXPIRY DATE EXP {MM/AA/AA} Once opened, use by 6 months. 
Jednom odčepljen/otvoren primijeniti u roku 6 mjeseci.
ROUTE(S) OF ADMINISTRATION Cutaneous use. 
PUT(EVI) PRIMJENE Za kožu
PACKAGE LEAFLET CORTAVANCE 0.584 mg/ml cutaneous spray solution for dogs 
UPUTA O VMP CORTAVANCE 0,584 mg/ml, sprej za kožu, otopina za pse
MARKETING AUTHORISATION HOLDER VIRBAC 
UPUTA O VMP
MARKETING AUTHORISATION NUMBER(S) Carton box with a PET bottle of 76ml: EU/2/06/069/001 
16. BROJ(EVI) ODOBRENJA ZA STAVLJANJE U PROMET Kartonska kutija s PET bočicom od 76ml: EU/2/06/069/001 Kartonska kutija s HDPE bočicom od 76ml: EU/2/06/069/004 17. BROJ PROIZVODNE SERIJE PROIZVOĐAČA Serija {broj}
If this happens, do not drive or use any tools or machines until you are feeling well again. 
nemojte voziti niti koristiti alate ili strojeve dok se ponovno ne počnete osjećati dobro.
• Difficulty in sleeping (insomnia). 
• Otežano spavanje (nesanica).
Date of latest renewal: 18 September 2017 
Datum posljednje obnove odobrenja: 18. rujna 2017
Response data are shown in Table 2. 
Odgovori su prikazani u Tablici 2.
Molecular response** 
Molekularni odgovor**
In addition, children have been treated in two phase I studies and one phase II study. 
Osim toga, djeca su liječena u dva ispitivanja faze I i jednom ispitivanju faze II.
Imatinib Teva may do the same to some other medicines. 
Imatinib Teva može to isto napraviti nekim drugim lijekovima.
Your doctor may prescribe a higher or lower dose depending on how you respond to the treatment. 
Liječnik Vam može propisati višu ili nižu dozu, ovisno o tome kako reagirate na liječenje.
PVC/PE/PVdC/PE/PVC//Al blisters OPA/Al/PVC//Al blisters 
PVC/PE/PVdC/PE/PVC//Al blisteri OPA/Al/PVC//Al blisteri
The suspension should be administered immediately after complete disintegration of the tablet(s). 
Suspenzija se mora primijeniti odmah nakon potpunog raspada tablete(a).
• Decreased or increased skin sensitivity. 
• Smanjena ili povećana osjetljivost kože.
If you think you may be allergic but are not sure, ask your doctor for advice. 
Ako mislite da bi mogli biti alergični, ali niste sigurni, posavjetujte se sa svojim liječnikom.
The amount of Imatinib Teva given will depend on your child's condition, body weight and height. 
Količina Imatiniba Teva koju je potrebno dati ovisiti će o stanju djeteta, tjelesnoj težini i visini.
10000 Zagreb Croatia 
10000 Zagreb
A major response (0-35%) combines both complete and partial responses. 
Veliki odgovor (0-35%) je kombinacija potpunih i djelomičnih odgovora.
Imatinib Teva can reduce the number of white blood cells, so you might get infections more easily. 
Imatinib Teva može smanjiti broj bijelih krvnih stanica, pa možete lakše dobiti infekciju.
Hands should be washed immediately after handling open capsules. 
Ruke se trebaju oprati odmah nakon rukovanja s otvorenim kapsulama.
• Rapid weight gain. 
• Brzo dobivanje na težini.
Not applicable Not applicable 
nije primjenjivo nije primjenjivo
Some children and adolescents taking Imatinib Teva may have slower than normal growth. 
Kod neke djece i adolescenata koji uzimaju Imatinib Teva rast može biti sporiji od normalnog.
Treatment with imatinib may be interrupted or the dose may be reduced, as recommended in section 4.2. 
Liječenje imatinibom može se prekinuti ili se doza može smanjiti, kao što je preporučeno u dijelu 4.2.
• Recurrence (reactivation) of hepatitis B infection when you have had hepatitis B in the past (a liver infection). 
• ponovna pojava (ponovna aktivacija) infekcije virusom hepatitisa B ako ste u prošlosti imali hepatitis B (infekciju jetre).
The annual rate of progression to accelerated phase or blast crisis decreased with time on therapy and was less than 1% annually in the fourth and fifth years. 
Godišnja stopa progresije u ubrzanu fazu ili blastičnu krizu smanjivala se s vremenom trajanja terapije, i bila je manja od 1% godišnje u četvrtoj i petoj godini.
Do not stop taking Imatinib Teva unless your doctor tells you to. 
Nemojte prestati uzimati Imatinib Teva, osim ako Vam to ne kaže liječnik.
• Unexpected bleeding or bruising (when you have not hurt yourself). 
• Neočekivano krvarenje ili pojava modrica (kada se niste ozlijedili).
Do not use any pack that is damaged or shows signs of tampering. 
Nemojte koristiti pakovanje koje je oštećeno ili na kojem su vidljivi znakovi otvaranja.
• Once the tablet has dissolved, drink everything in the glass straight away. 
• Jednom kad se tableta otopi, odmah popijte sav sadržaj čaše.
Treatment was discontinued permanently because of liver laboratory abnormalities in less than 1% of CML patients. 
Liječenje je trajno ukinuto zbog abnormalnih jetrenih laboratorijskih nalaza u manje od 1% bolesnika s KML-om.
If you have any questions about how Imatinib Teva works or why this medicine has been prescribed for you, ask your doctor. 
Ako imate bilo kakvih pitanja o tome na koji način djeluje Imatinib Teva, ili zašto je taj lijek Vama propisan, obratite se svom liječniku.
Cytogenetic abnormalities were evaluated in 117 of the total population of 176 patients. 
Citogenetske abnormalnosti su evaluirane u 117 od ukupno 176 bolesnika.
There were 59% males and 41% females; 89.9% caucasian and 4.7% black patients. 
Bilo je 59% muškaraca i 41% žena; 89,9% bijelaca i 4,7% crnaca.
A confirmed haematological response was achieved in 71.5% of patients (Table 3). 
Potvrđeni hematološki odgovor je postignut u 71,5% bolesnika (Tablica 3).
As reported in a recent publication 21 of these 65 patients also achieved complete molecular remission with a median follow-up of 28 months (range 13-67 months). 
Kao što je zabilježeno u nedavnoj publikaciji, 21 od tih 65 bolesnika također je postiglo kompletnu molekularnu remisiju s medijanom praćenja od 28 mjeseci (raspon 13-67 mjeseci).
Your doctor has prescribed Imatinib Teva because you suffer from a serious condition. 
Vaš liječnik je propisao Imatinib Teva, jer patite od ozbiljnog stanja.
Imatinib Teva can help you to fight this condition. 
Imatinib Teva Vam može pomoći u borbi protiv tog stanja.
While you are taking Imatinib Teva your doctor will regularly check whether the medicine is working. 
Dok uzimate Imatinib Teva, liječnik će redovito pratiti da li lijek djeluje.
You may become more sensitive to the sun while taking Imatinib Teva. 
Možete postati osjetljiviji na sunce tijekom uzimanja Imatinib Teva.
Similar findings were found based on a 18months landmark analysis. 
Slični nalazi su nađeni i na temelju analize pokazatelja nakon 18 mjeseci.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription (such as paracetamol) and including herbal medicines (such as St. John's Wort). 
Obavijestite svog liječnika ili ljekarnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove, uključujući lijekove dobivene bez recepta (poput paracetamola) i biljne pripravke
Imatinib pharmacokinetics has not been specifically studied in the elderly. 
Farmakokinetika imatiniba nije specifično ispitivana u starijih osoba.
8 g to 10 g (single dose): Vomiting and gastrointestinal pain have been reported. 
8 g do 10 g (jednokratna doza): zabilježeni su povraćanje i bolovi u trbuhu.
The complete molecular response rate was 48% (49 out of 102 evaluable patients). 
Kompletni molekularni odgovor postignut je u 48% (49 od 102 evaluirana bolesnika).
Other medicines and Imatinib Teva 
Drugi lijekovi i Imatinib Teva
235 adult patients with accelerated phase disease were enrolled. 
Uključeno je 235 odraslih bolesnika s bolešću u ubrzanoj fazi.
Out of the 12 patients enrolled, 9 responded, one completely and 8 partially. 
Od 12 uključenih bolesnika, 9 je imalo odgovor, jedan kompletni, a 8 parcijalni.
At the same dose, the number of stillborn pups as well as those dying between postpartum days 0 and 4 was increased. 
Pri istoj dozi povećao se broj mrtvorođenih mladunaca, kao i onih koji su uginuli postpartalno između 0. i 4. dana.
• Slowing of growth in children and adolescents. 
• Usporen rast kod djece i adolescenata.
Median age was 51 years (range 18-70 years), with 21.9% of patients ≥ 60 years of age. 
Medijan dobi je iznosio 51 godinu (u rasponu od 18-70 godina), kod čega je 21,9% bolesnika bilo ≥60 godina.
The prescribed dose should be administered orally with a meal and a large glass of water to minimise the risk of gastrointestinal irritations. 
Propisanu dozu treba primjenjivati peroralno, uz obrok i veliku čašu vode, da bi se rizik od gastrointestinalnih iritacija sveo na najmanju moguću mjeru.
The most important changes included cardiac hypertrophy and dilatation, leading to signs of cardiac insufficiency in some animals. 
Najvažnije promjene uključivale su srčanu hipertrofiju i dilataciju, što je, u nekih životinja, dovelo do znakova srčane insuficijencije.
These events can usually be managed with either a reduction of the dose or an interruption of treatment with imatinib, but can in rare cases lead to permanent discontinuation of treatment. 
Te se epizode obično mogu liječiti ili smanjenjem doze ili prekidanjem liječenja imatinibom, no u rijetkim slučajevima mogu dovesti i do trajnog ukidanja lijeka.
When needed, discontinuation of Imatinib Teva treatment may be considered. 
Ukoliko je potrebno, može se razmotriti prekid liječenja Imatinibom Teva.
What Imatinib Teva is and what it is used for 
Što je Imatinib Teva i za što se koristi
Treatment resulted in worsening of normally suppressed malarial infections in these animals. 
Liječenje je u tih životinja rezultiralo pogoršanjem malarijskih infekcija koje su u normalnim okolnostima suprimirane.
During treatment with Imatinib Teva, tell your doctor straight away if you put on weight very quickly. 
Tijekom liječenja Imatinib Tevaom odmah obavijestite svog liječnika ako vrlo brzo dobivate na težini.
A complete haematological response was achieved in 95% of patients. 
Potpuni je hematološki odgovor postignut u 95%
For patients with reduction in Bcr-Abl transcripts of at least 3 logarithms at 12 months, the probability of remaining free from progression to accelerated phase/blast crisis was 99% at 84 months. 
Za bolesnike sa smanjenjem Bcr-Abl transkripcija za najmanje 3 logaritma nakon 12 mjeseci, vjerojatnost zadržavanja stanja bez progresije u ubrzanu fazu/blastičnu krizu bila je 99% nakon 84 mjeseca.
Importantly, 27.7% of patients also achieved a major cytogenetic response, which was complete in 20.4% (confirmed 16%) of patients. 
Važno je napomenuti da je 27,7% bolesnika također postiglo veliki citogenetski odgovor, koji je bio potpun u 20,4% (potvrđeno 16%) bolesnika.
The degree of cytogenetic response and molecular response had a clear effect on long-term outcomes in patients on imatinib. 
Stupanj citogenetskog odgovora i molekularnog odgovora imao je jasan učinak na dugotrajne ishode u bolesnika na imatinibu.
5 patients responded, 3 completely and 2 partially. 
5 bolesnika je imalo odgovor, 3 kompletni i 2 parcijalni.
Ki values in human liver microsomes were 27, 7.5 and 7.9 µmol/l, respectively. 
Ki vrijednosti u jetrenim mikrosomima čovjeka bile su 27, 7,5, odnosno 7,9 µmol/l.
• Dry mouth, dry skin or dry eye. 
• Suhoća usta, suhoća kože ili suho oko.
260 patients with myeloid blast crisis were enrolled. 
U ispitivanje je uključeno 260 bolesnika s mijeloičnom blastičnom krizom.
When female rats were dosed 14 days prior to mating and through to gestational day 6, there was no effect on mating or on number of pregnant females. 
Kada su ženke štakora dobivale dozu tijekom 14 dana prije parenja pa sve do 6. dana gestacije, nije bilo učinka na parenje ili na broj skotnih ženki.
• Pain in your hips or difficulty walking. 
• Bol u kukovima ili otežano hodanje.
The median time to progression in the overall population of 411 patients with relapsed/refractory Ph+ ALL ranged from 2.6 to 3.1 months, and median overall survival in the 401 evaluable patients ranged from 4.9 to 9 months. 
Medijan vremena do progresije u ukupnoj populaciji od 411 bolesnika s recidivirajućom ili refraktornom Ph+ ALL kretao se od 2,6 do 3,1 mjesec, a medijan ukupnog preživljenja kod 401 evaluiranog bolesnika kretao se od 4,9 do 9 mjeseci.
The patients were distributed in three main categories: haematological failure (29%), cytogenetic failure (35%), or intolerance to interferon (36%). 
Bolesnici su bili raspoređeni u tri glavne kategorije: hematološki neuspjeh (29%), citogenetski neuspjeh (35%) ili nepodnošenje interferona (36%).
The age of the DFSP patients ranged from 23 to 75 years; DFSP was metastatic, locally recurrent following initial resective surgery and not considered amenable to further resective surgery at the time of study entry. 
DFSP-om kretala se od 23 do 75 godina; DFSP je bio metastazirajući, lokalno recidivirajući nakon inicijalnog resekcijskog kirurškog zahvata te nije smatran podobnim za dodatni resekcijski kirurški zahvat u trenutku uključivanja u studiju.
The yearly rates of progression of any type for imatinib also decreased over time. 
Kod imatiniba su se godišnje stope progresije bilo koje vrste također smanjivale s vremenom.
Your doctor will discuss with you the possible risks of taking Imatinib Teva during pregnancy. 
Liječnik će Vam objasniti moguće rizike od uzimanja Imatiniba Teva tijekom trudnoće.
The median duration of second-line treatment with imatinib was 64 months. 
Medijan trajanja druge linije liječenja za imatinib bio je 64 mjeseca.
Resume treatment with imatinib at previous dose (i.e. before severe adverse reaction). 
Nastaviti imatinib u prijašnjoj dozi (tj. prije teške nuspojave).
Non-neoplastic lesions not identified in earlier preclinical studies were the cardiovascular system, pancreas, endocrine organs and teeth. 
Neneoplastičke lezije koje nisu identificirane u prethodnim nekliničkim ispitivanjima javile su se u kardiovaskularnom sustavu, gušterači, endokrinim organima i zubima.
• Blood clots in small blood vessels (thrombotic microangiopathy). 
• Krvni ugrušci u malim krvnim žilama (trombotična mikroangiopatija).
Imatinib Teva may cause your body to retain water (severe fluid retention). 
Imatinib Teva može izazvati zadržavanje vode u tijelu (teška retencija tekućine).
All patients received imatinib and consolidation chemotherapy (see Table 4) after induction and the levels of bcr-abl transcripts were identical in the two arms at 8 weeks. 
Svi su bolesnici primili imatinib i konsolidacijsku kemoterapiju (vidjeti Tablicu 3) nakon indukcije, a razine bcr-abl prijepisa bile su identične u oba kraka nakon 8 tjedana.
The median duration of therapy in study B2225 was 6.2 months, with a maximum duration of 24.3 months. 
Medijan trajanja terapije u studiji B2225 iznosio je 6,2 mjeseca, s maksimalnim trajanjem od
Since studies in animals have shown reproductive toxicity, and the potential risk for the human foetus is unknown, women of child-bearing potential who open capsules should be advised to handle the contents with caution and avoid skin-eye contact or inhalation (see section 4.6). 
Budući da su ispitivanja kod životinja pokazala reproduktivnu toksičnost, a potencijalni rizik za ljudski plod nije poznat, žene u reproduktivnoj dobi koje otvaraju kapsule treba savjetovati da pažljivo rukuju sa sadržajem te da izbjegavaju kontakt s kožom i očima ili inhaliranje (vidjeti dio 4.6).
Traces of the dissolved tablets may be left behind in the glass. 
Ostatke otopljenih tableta možete ostaviti u čaši.
The active substance imatinib demonstrates an environmental risk for sediment organisms. 
Djelatna tvar imatinib predstavlja ekološki rizik za sedimentne organizme.
Immune system disorders Not known 
Poremećaji imunološkog sustava Nepoznato:
The high rate of CHR is accompanied by the development of a complete cytogenetic response (CCyR) of 65% which is comparable to the results observed in adults. 
Visoka stopa CHR-a je praćena razvojem kompletnog citogenetskog odgovora (CCyR) od 65% što je usporedivo s rezultatima dobivenim u odraslih.
Chronic phase, Interferon failure 532 adult patients were treated at a starting dose of 400 mg. 
Kronična faza, neuspjeh interferona 532 odrasla bolesnika liječena su s početnom dozom od 400 mg.
In the F1 offspring, at the same dose level, mean body weights were reduced from birth until terminal sacrifice and the number of litters achieving criterion for preputial separation was slightly decreased. 
Pri istoj dozi u F1 potomaka, smanjile su se srednje tjelesne težine od poroda sve do konačnog žrtvovanja, a broj okota koji su postigli kriterij za prepucijsku separaciju bio je malo smanjen.
The results observed in a population of 211 newly diagnosed Ph+ ALL patients in four uncontrolled clinical studies (AAU02, ADE04, AJP01 and AUS01) are consistent with the results described above. 
Rezultati uočeni u populaciji od 211 novodijagnosticiranih bolesnika s Ph+ ALL-om u četiri nekontrolirana klinička ispitivanja (AAU02, ADE04, AJP01 i AUS01) su u skladu s gore opisanim rezultatima.
Patients had received a median of 14 months of prior IFN therapy at doses ≥ 25 x 106 IU/week and were all in late chronic phase, with a median time from diagnosis of 32 months. 
Bolesnici su prethodno primali IFN terapiju u medijanu trajanja od 14 mjeseci u dozama ≥25 x 106 IU/tjedan i svi su bili u završnoj kroničnoj fazi, sa medijanom vremena od postavljanja dijagnoze od 32 mjeseca.
As expected on the basis of the study design, no difference was observed in remission duration, disease-free survival or overall survival, although patients with complete molecular response and remaining in minimal residual disease had a better outcome in terms of both remission duration (p=0.01) and disease-free survival (p=0.02). 
Kao što se očekivalo na temelju dizajna studije, nije uočena razlika u trajanju remisije, preživljenju bez znakova ili ukupnom preživljenju, premda su bolesnici s kompletnim molekularnim odgovorom i s minimalnom rezidualnom bolešću imali bolji ishod u smislu dužine remisije (p=0,01) i preživljenja bez znakova bolesti (p=0,02).
Some medicines can interfere with the effect of Imatinib Teva when taken together. 
Neki lijekovi mogu utjecati na djelovanje Imatiniba Teva kada se uzimaju zajedno.
Dose increase from 100 mg to 400 mg may be considered in the absence of adverse drug reactions if assessments demonstrate an insufficient response to therapy. 
Povećanje doze od 100 mg do 400 mg može se razmotriti u odsustvu nuspojava, ako se pregledom utvrdi neadekvatan odgovor na terapiju.
• Sudden swelling and redness of the skin (signs of a skin infection called cellulitis). 
• Iznenadno oticanje i crvenilo kože (znakovi kožne infekcije zvane celulitis).
Study 0102 38-month data Myeloid blast crisis (n=260) 
38-mjesečni podaci Mijeloična blastična kriza (n=260)
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i blisteru nakon iza oznake EXP.
In this study, 31% of patients achieved a haematological response (36% in previously untreated patients and 22% in previously treated patients). 
U tom je ispitivanju 31% bolesnika postiglo hematološki odgovor (36% u skupini prethodno neliječenih bolesnika i 22% u skupini prethodno liječenih bolesnika).
• Unusual hair loss or thinning. 
• Neuobičajen gubitak ili prorijeđenost kose.
Due to the observational nature of this registry, haematologic, cytogenetic and molecular assessment data were available for 22, 9 and 17 of the 23 enrolled patients, respectively. 
Zbog opservacijske prirode ovog registra, podaci hematološke, citogenetske i molekularne procjene bili su dostupni za 22, 9 odnosno 17 od
Disease-free survival (DFS) and overall survival (OS) constantly exceeded 1 year and were superior to historical control (DFS p<0.001; OS p<0.0001) in two studies (AJP01 and AUS01). 
Preživljenje bez znakova (DFS) i ukupno preživljenje (OS) stalno premašuju 1 godinu te su superiorni nad prethodnim kontrolama (DFS p<0,001; OS p<0,0001) u dva ispitivanja (AJP01 i AUS01).
In clinical trials, there was an increased incidence of these events in the elderly and those with a prior history of cardiac disease. 
U kliničkim je ispitivanjima zabilježena povećana incidencija tih događaja u starijih osoba te u onih s anamnezom srčanih bolesti.
Mogilska 80, 31-546 Krakow Poland 
Mogilska 80, 31-546 Krakow Poljska
Alternating chemotherapy course: high dose chemotherapy with MTX 1 g/m2 i.v. 
Izmjenični tijek kemoterapije: visoka doza kemoterapije s MTX 1 g/m2
If anti-ADAMTS13-antibody is elevated in conjunction with low ADAMTS13 activity, treatment with Imatinib Teva should not be resumed. 
Ako su anti-ADAMTS13-protutijela povišena istodobno sa sniženom ADAMTS13 aktivnosti, liječenje Imatinibom Teva ne smije se nastaviti.
In all clinical studies 38-40% of patients were ≥ 60 years of age and 10-12% of patients were ≥ 70 years of age. 
U svim kliničkim ispitivanjima 38-40 % bolesnika bilo je u dobi ≥60 godina, a 10-12% bolesnika bilo je u dobi ≥70 godina.
Haematological and cytogenetic responses have been sustained for a median of 49 months (range 19-60) and 47 months (range 16-59), respectively. 
Hematološki i citogenetski odgovori su se održali za medijan od 49 mjeseci (raspon 19-60), odnosno 47 mjeseci (raspon 16-59).
They may increase or decrease the effect of Imatinib Teva, either leading to increased side effects or making Imatinib Teva less effective. 
Oni mogu povećati ili smanjiti učinak Imatiniba Teva bilo povećanjem nuspojava ili smanjenjem učinka Imatiniba Teva.
All 65 FIP1L1-PDGFRα fusion kinase positive patients achieved a CHR sustained for months (range from 1+ to 44+ months censored at the time of the reporting). 
Svih 65 bolesnika s pozitivnom FIP1L1-PDGFRα fuzijskom kinazom postiglo je CHR koji se održao mjesecima (raspon od 1+ do 44+ mjeseci, izostavljeno u trenutku izvještavanja).
Based on population pharmacokinetic analysis in CML patients, there was a small effect of age on the volume of distribution (12% increase in patients > 65 years old). 
Na temelju analize farmakokinetike populacije bolesnika s KML-om, učinak dobi na volumen raspodjele bio je malen (povećanje od 12% u bolesnika starih >65 godina).
The length of the capsule is from 23.0 mm to 23.6 mm and the width is 8.53 mm. 
Duljina kapsule je od 23,0 mm do 23,6 mm, a širina iznosi 8,53 mm.
Neoplasm benign, malignant and unspecified (including cysts and polyps) Rare 
Dobroćudne, zloćudne i nespecificirane novotvorine (uključujući ciste i polipe)
- If you are being treated for MDS/MPD: 
Ako se liječite zbog MDS/MPD-a:
Severe elevation of transaminases (<5%) or bilirubin (<1%) was seen in CML patients and was usually managed with dose reduction or interruption (the median duration of these episodes was approximately one week). 
Veliko povišenje vrijednosti transaminaza (<5%) ili bilirubina (<1%) uočeno je u bolesnika s KML-om i obično je liječeno smanjenjem doze ili prekidom terapije (medijan trajanja tih epizoda bio je približno tjedan dana).
Myeloid blast crisis 
Mijeloična blastična kriza
One of these intermediates was also positive in the mouse lymphoma assay. 
Jedan od tih međuproizvoda je također bio pozitivan na uzorku mišjeg limfoma.
Two intermediates of the manufacturing process, which are also present in the final product, are positive for mutagenesis in the Ames assay. 
Dva međuproizvoda, koji su također prisutni u gotovom proizvodu, su u Amesovom testu pozitivna na mutagenezu.